Sentinel Lymph Node Biopsy for High-Risk Cutaneous Squamous Cell Carcinoma of the Head and Neck

Nouri, Keyvan; Rivas, Maria Patricia; Pedroso, Felipe E.; Bhatia, Rita; Civantos, Francisco

doi:10.1001/archderm.140.10.1284-a

Cited by 30 publications

(27 citation statements)

References 5 publications

(9 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A review of all case series reporting SLNB in cSCC is detailed in Table IV. 13,18,28,[41][42][43][44][45][46][47][48][49][50][51][52] Our systematic review identified an overall positive rate for SLNB of 13.9% (32 of 231 patients) and a false-negative rate of 4.6% (10 of 215 patients) in cSCC. The authors usually stated that patients had high-risk factors for lymph node involvement.…”

Section: Systematic Review Resultsmentioning

confidence: 99%

High-risk cutaneous squamous cell carcinoma and the emerging role of sentinel lymph node biopsy: A literature review

Navarrete‐Dechent

Veness

Droppelmann

et al. 2015

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

Section: Systematic Review Resultsmentioning

confidence: 99%

High-risk cutaneous squamous cell carcinoma and the emerging role of sentinel lymph node biopsy: A literature review

Navarrete‐Dechent

Veness

Droppelmann

et al. 2015

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

“…Three case series [27-29] and one case report [31] were excluded since these patients were later combined into larger institutional case series resulting in a total of 130 evaluable cases (Table 2). All of the studies, except Hatta et al [30] clearly designated cutaneous SCC cases with at least one high-risk feature.…”

Section: Resultsmentioning

confidence: 99%

Sentinel lymph node biopsy for high-risk cutaneous squamous cell carcinoma: clinical experience and review of literature

2011

View full text Add to dashboard Cite

High-risk cutaneous squamous cell carcinoma (SCC) is associated with an increased risk of metastases. The role of sentinel lymph node (SLN) biopsy in these patients remains unclear. To address this uncertainty, we collected clinical data on six patients with clinical N0 high-risk SCC that underwent SLN biopsy between 1999 and 2006 and performed a literature review of SLN procedures for SCC to study the utility of SLN biopsy. There were no positive SLN identified among six cases and there was one local and one distant recurrence on follow-up. Literature review identified 130 reported cases of SLN biopsy for SCC. The SLN positivity rate was 14.1%, 10.1%, and 18.6%; false negative rate was 15.4%, 0%, and 22.2%; and the negative predictive value was 97.8%, 100%, and 95.2% for all sites, head/neck, and truncal/extremity sites, respectively. SLN biopsy remains an investigational staging tool in clinically node-negative high-risk SCC patients. The higher false negative rate and lower negative predictive value among SCC of the trunk/extremity compared to SCC of the head/neck sites suggests a more cautious approach when treating patients with the former. Given the paucity of long-term follow up, an emphasis is placed upon the need for close surveillance regardless of SLN status.

show abstract

“…Therapeutic lymphadenectomy should be performed in case of lymphadenopathy, while the role of sentinel lymph node biopsy (SLNB) for staging EPC remains unknown, and probably may be reserved in cases of histological aggressiveness or intralymphatic permeation by the primary tumor [16-20]. In our case, tumor cells were detected in the needle aspiration of the left axillary lymph node and an axillary lymphadenectomy was performed.…”

Section: Discussionmentioning

confidence: 98%

“…Its use is generally reserved for palliative care and tumor response is both partial and inconsistent [17-20]. …”

Section: Discussionmentioning

confidence: 99%

Metastatic eccrine porocarcinoma: report of a case and review of the literature

Marone¹,

Caracò²,

Anniciello³

et al. 2011

World J Surg Onc

View full text Add to dashboard Cite

Eccrine porocarcinoma (EPC) is a rare type of skin cancer arising from the intraepidermal portion of eccrine sweat glands or acrosyringium, representing 0.005-0.01% of all cutaneous tumors. About 20% of EPC will recur and about 20% will metastasize to regional lymph nodes. There is a mortality rate of 67% in patients with lymph node metastases. Although rare, the occurrence of distant metastases has been reported.We report a case of patient with EPC of the left arm, with axillary nodal involvement and subsequent local relapse, treated by complete lymph node dissection and electrochemotherapy (ECT).EPC is an unusual tumor to diagnose. Neither chemotherapy nor radiation therapy has been proven to be of clinical benefit in treating metastatic disease. Although in the current case the short follow-up period is a limitation, we consider in the management of EPC a therapeutic approach involving surgery and ECT, because of its aggressive potential for loregional metastatic spread.

show abstract

Sentinel Lymph Node Biopsy for High-Risk Cutaneous Squamous Cell Carcinoma of the Head and Neck

Cited by 30 publications

References 5 publications

High-risk cutaneous squamous cell carcinoma and the emerging role of sentinel lymph node biopsy: A literature review

High-risk cutaneous squamous cell carcinoma and the emerging role of sentinel lymph node biopsy: A literature review

Sentinel lymph node biopsy for high-risk cutaneous squamous cell carcinoma: clinical experience and review of literature

Metastatic eccrine porocarcinoma: report of a case and review of the literature

Contact Info

Product

Resources

About